Q-omics provides the consensus-scored ZNF385C profile across patient tissues and cancer cell-line models. ZNF385C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF385C is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZNF385C RNA expression shows 16,807 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where ZNF385C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF385C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF385C survival associations across molecular data types. ZNF385C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF385C RNA expression–survival associations across cancer types. High ZNF385C expression shows unfavorable associations in CESC, KIRP and ACC, but favorable associations in UVM, KIRC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF385C RNA expression.
This table summarizes ZNF385C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF385C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF385C shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, BLCA, LUSC and CHOL. The KIRC box plot shows higher ZNF385C RNA expression in tumor versus normal tissue (log2 FC = +0.388, t-test p < 0.001).
This table shows molecular features associated with ZNF385C in patient tissues and cancer cell lines. In patient samples, ZNF385C shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF385C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
